SCHEMBL23027800

SCHEMBL23027800

COc1ccc(C(=O)Nc2nc(CCN3C(=O)c4ccccc4C3=O)cs2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.59
ALDH1A1 P00352 4/20 0.59
MAPT P10636 5/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
LMNA P02545 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MAPK1 P28482 4/20 0.53
PKM P14618 1/20 0.51
KDM4E B2RXH2 4/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027837 0.82 ALDH1A1 (0.54) ALDH1A1MAPTKMT2ALMNANPSR1
SCHEMBL29451875 0.77 ALDH1A1 (0.65) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL23027818 0.75 POLB (0.61) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL23027787 0.75 POLB (0.84) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL307371 0.74 ROCK2 (0.57) ALDH1A1LMNANPSR1HSD17B10MAPK1
SCHEMBL17107236 0.74 ADORA3 (0.73) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL3939486 0.74 AOC3 (0.63) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL23027788 0.73 POLB (0.54) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL3943482 0.73 POLB (0.59) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL9385833 0.73 KMT2A (0.76) POLBALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202783-A1 Use Of ADAM9 Inhibitor As Immunomodulator CHINA MEDICAL UNIVERSITY (TW) 2022-06-30 US disclosed
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof CHINA MEDICAL UNIVERSITY (TW) 2022-06-14 US disclosed
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof CHINA MEDICAL UNIVERSITY (TW) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof ADAM9, ADAM8, ADAM17 POLB 2797/4885ALDH1A1 818/4885MAPT 1737/4885
US-20220202783-A1 Use Of ADAM9 Inhibitor As Immunomodulator ADAM9, ADAM17, ADAM10 POLB 4111/4885ALDH1A1 736/4885MAPT 3674/4885
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof ADAM9, ADAM8, ADAM17 POLB 2797/4885ALDH1A1 818/4885MAPT 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.